<DOC>
	<DOCNO>NCT01697488</DOCNO>
	<brief_summary>This observational study evaluate safety , efficacy , quality life predictive/selection factor Avastin ( bevacizumab ) combination carboplatin/paclitaxel first line patient advance epithelial ovarian , fallopian tube primary peritoneal cancer clinical practice . Data eligible patient collect 15 month treatment 12 month follow-up . A second recruitment phase open focus patient &gt; /= 70 year .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Combination With Carboplatin/Paclitaxel First Line Patients With Advanced Epithelial Ovarian , Fallopian Tube Primary Peritoneal Cancer ( OTILIA )</brief_title>
	<detailed_description />
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Study phase 1 : Patients age &gt; /= 18 year Study phase 2 : Patients age &gt; /= 70 year Newly diagnose advanced epithelial ovarian cancer , fallopian tube carcinoma primary peritoneal cancer indication firstline carboplatin/paclitaxel chemotherapy combination Avastin Contraindications Avastin accord Summary Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>